Key result
SGLT2i show potential to modify cognitive impairment in CKD by targeting vascular risk factors.
Why the study?
Cognitive impairment and kidney function decline often coexist in aging individuals with CKD, and the potential disease modifying effects of SGLT2 inhibitors on cognitive impairment in CKD are under investigation.
Do SGLT2 inhibitors prevent cognitive impairment in individuals with chronic kidney disease?
Do SGLT2 inhibitors prevent cognitive impairment in individuals with chronic kidney disease?
This narrative review explores the hypothesis that SGLT2 inhibitors may offer disease-modifying benefits for cognitive impairment in patients with chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Does not support routine use for cognitive protection in CKD; leaves open the need for dedicated RCTs.
Noel et al. (2022) conducted a review in Chronic kidney disease and cognitive impairment. SGLT2 inhibitors was evaluated. SGLT2 inhibitors demonstrate potential disease-modifying properties in cognitive impairment among individuals with chronic kidney disease by targeting vascular risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: